The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells

Scientific Reports

Volumn 9, Issue 1, 2019, Pages

  Riahi Chebbi, Ichrak ^a,c   Souid, Soumaya ^a,c   Othman, Houcemeddine ^a,c   Haoues, Meriam ^a,c   Karoui, Habib ^a,c   Morel, Alain ^b   Srairi Abid, Najet ^a,c   Essafi, Makram ^a,c   Essafi Benkhadir, Khadija ^a,c  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; KAEMPFEROL DERIVATIVE; PHENOL DERIVATIVE;

CELL CYCLE CHECKPOINT; CELL SURVIVAL; COLON TUMOR; DRUG EFFECT; DRUG RESISTANCE; HUMAN; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; KAEMPFEROLS; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85060180701     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-36808-z     Document Type: Article

References (91)

1. Murphy, N. et al. Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study. Clin Gastroenterol Hepatol, 10.1016/j.cgh.2018.07.030 (2018).
2. Bray, F. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 10.3322/caac.21492 (2018).
3. Landre, T. et al. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. Int J Colorectal Dis 30, 1305–1310 (2015).
4. Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E. & Rodriguez Yoldi, M. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci 18, 197 (2017).
5. Webber, E. M., Kauffman, T. L., O’Connor, E. & Goddard, K. A. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 15, 156 (2015).
6. Xie, T. et al. MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer. Cell Physiol Biochem 40, 62–76 (2016).
7. Touil, Y. et al. Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis. Clin Cancer Res 20, 837–846 (2014).
8. Jones, V. S. et al. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim Biophys Acta - Rev Cancer 1865, 255–265 (2016).
9. Tang, J.-C., Feng, Y.-L., Liang, X. & Cai, X.-J. Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges. Chin Med J (Engl) 129, 456–63 (2016).
10. Zheng, Y., Zhou, J. & Tong, Y. Gene signatures of drug resistance predict patient survival in colorectal cancer. Pharmacogenomics J 15, 135–43 (2015).
11. Deng, J., Wang, Y., Lei, J., Lei, W. & Xiong, J. P. Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance. Tumor Biol 39, 101042831769755 (2017).
12. Zhang, N., Yin, Y., Xu, S.-J. & Chen, W.-S. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13, 1551–69 (2008).
13. El Khoury, F., Corcos, L., Durand, S., Simon, B. & Le Jossic-Corcos, C. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells. Int J Oncol 49, 2558–2568 (2016).
14. Kim, A.-Y., Kwak, J.-H., Je, N. K., Lee, Y.-H. & Jung, Y.-S. Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells. Toxicol Res 31, 151–6 (2015).
15. Jiang, Z.-S., Sun, Y.-Z., Wang, S.-M. & Ruan, J.-S. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer 8, 2319–2327 (2017).
16. González-Sarrías, A., Tomé-Carneiro, J., Bellesia, A., Tomás-Barberán, F. A. & Espín, J. C. The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct 6, 1460–9 (2015).
17. Abdal Dayem, A. et al. The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. Nutrients 8, 581 (2016).
18. Abaza, M. S. I., Orabi, K. Y., Al-Quattan, E. & Al-Attiyah, R. J. Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer. Cancer Cell Int 15, 46 (2015).
19. Hussain, S. A. et al. Natural Polyphenols in Cancer Chemoresistance. Nutr Cancer 68, 879–891 (2016).
20. Aung, T., Qu, Z., Kortschak, R. & Adelson, D. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. Int J Mol Sci 18, 656 (2017).
21. Lee, J., Kang, J.-S., Choi, B.-Y. & Keum, Y.-S. Sensitization of 5-Fluorouracil-Resistant SNUC5 Colon Cancer Cells to Apoptosis by α-Mangostin. Biomol Ther (Seoul) 24, 604–609 (2016).
22. Taylor, W. F. & Jabbarzadeh, E. The use of natural products to target cancer stem cells. Am J Cancer Res 7, 1588–1605 (2017).
23. Findlay, V. J. et al. SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther 13, 2713–26 (2014).
24. Violette, S. et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J cancer 98, 498–504 (2002).
25. Riahi-Chebbi, I. et al. Quince peel polyphenolic extract blocks human colon adenocarcinoma LS174 cell growth and potentiates 5-fluorouracil efficacy. Cancer Cell Int 16, 1 (2015).
26. Yaheya, M. & Ismail, M. Review Article DRUG-FOOD INTERACTIONS AND ROLE OF PHARMACIST. Asian Journal of Pharmaceutical and Clinical Research 2, 1–10 (2009).
27. Ijichi, K., Adachi, M., Ogawa, T., Hasegawa, Y. & Murakami, S. Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells. Anticancer Res 34, 2907–11 (2014).
28. Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y. & Sakuragi, N. Apoptosis and Molecular Targeting Therapy in Cancer. Biomed Res Int 2014, 1–23 (2014).
29. Chen, A. Y. & Chen, Y. C. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem 138, 2099–2107 (2013).
30. Huang, C.-Y. & Yu, L. C.-H. Pathophysiological mechanisms of death resistance in colorectal carcinoma. World J Gastroenterol 21, 11777–92 (2015).
31. Grossi, V., Peserico, A., Tezil, T. & Simone, C. p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol 20, 9744 (2014).
32. Wang, Z. et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 35, S224–S243 (2015).
33. Aubry, K., Labourey, J. L., Bessède, J. P., Tubiana-Mathieu, N. & Rigaud, M. Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study. Clin Med Oncol 2, 27–35 (2008).
34. Liu, T., Lin, Y., Wen, X., Jorissen, R. N. & Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35, D198–D201 (2007).
35. Phan, J. et al. Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors. J Biol Chem 276, 14170–7 (2001).
36. Goettert, M., Schattel, V., Koch, P., Merfort, I. & Laufer, S. Biological Evaluation and Structural Determinants of p38α Mitogen-Activated-Protein Kinase and c-Jun-N-Terminal Kinase 3 Inhibition by Flavonoids. ChemBioChem 11, 2579–2588 (2010).
37. Anreddy, N. et al. Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules 19, 13848–13877 (2014).
38. Cao, J., Han, J., Xiao, H., Qiao, J. & Han, M. Effect of Tea Polyphenol Compounds on Anticancer Drugs in Terms of Anti-Tumor Activity, Toxicology, and Pharmacokinetics. Nutrients 8 (2016).
39. van Dijk, D. et al. Slow-growing cells within isogenic populations have increased RNA polymerase error rates and DNA damage. Nat Commun 6, 7972 (2015).
40. Dallas, N. A. et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69, 1951–7 (2009).
41. Stadler, M. et al. Exclusion from spheroid formation identifies loss of essential cell-cell adhesion molecules in colon cancer cells. Sci Rep 8, 1151 (2018).
42. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15, 178–96 (2014).
43. Canel, M., Serrels, A., Frame, M. C. & Brunton, V. G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. 10.1242/jcs.100115.
44. Fu, Y. et al. Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation. Cell Death Dis 5, e983 (2014).
45. Focaccetti, C. et al. Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes. PLoS One 10, e0115686 (2015).
46. Guo, X. et al. Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res 28, 9–14 (2008).
47. Tadano, T. et al. MicroRNA-320 family is downregulated in colorectal adenoma and affects tumor proliferation by targeting CDK6. World J Gastrointest Oncol 8, 532–42 (2016).
48. Peng, Y. et al. Expression of pim-1 in Tumors, Tumor Stroma and Tumor-Adjacent Mucosa Co-Determines the Prognosis of Colon Cancer Patients. PLoS One 8, e76693 (2013).
49. Anders, L. et al. A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells. Cancer Cell 20, 620–634 (2011).
50. Moro, T. et al. Inhibition of Cdk6 expression through p38 MAP kinase is involved in differentiation of mouse prechondrocyte ATDC5. J Cell Physiol 204, 927–933 (2005).
51. Lu, H., Chang, D. J., Baratte, B., Meijer, L. & Schulze-Gahmen, U. Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin. J Med Chem 48, 737–743 (2005).
52. Holder, S. et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. 10.1158/1535-7163.MCT-06-0397.
53. Magnuson, N. S., Wang, Z., Ding, G. & Reeves, R. Why target PIM1 for cancer diagnosis and treatment? 10.2217/fon.10.106.
54. Gupta, S. C. et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16, 1295–322 (2012).
55. Du, M.-D., He, K.-Y., Qin, G., Chen, J. & Li, J.-Y. Adriamycin resistance-associated prohibitin gene inhibits proliferation of human osteosarcoma MG63 cells by interacting with oncogenes and tumor suppressor genes. Oncol Lett 12, 1994–2000 (2016).
56. Dick, F. A. & Rubin, S. M. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 14, 297–306 (2013).
57. Singh, S. K., Banerjee, S., Acosta, E. P., Lillard, J. W. & Singh, R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a and pathway. Oncotarget 8, 17216–17228 (2017).
58. Wiegering, A. et al. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Neoplasia 19, 301–309 (2017).
59. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269–83 (2012).
60. Kiedrowski, M. & Mroz, A. The effects of selected drugs and dietary compounds on proliferation and apoptosis in colorectal carcinoma. Contemp Oncol (Poznan, Poland) 18, 222–6 (2014).
61. Xie, C. Q. et al. Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways. Oncol Lett 12, 3586–3590 (2016).
62. Yadav, V., Varshney, P., Sultana, S., Yadav, J. & Saini, N. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer 15, 581 (2015).
63. Zhang, L. et al. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Int J Mol Med 36, 957–66 (2015).
64. Nho, R. S. & Hergert, P. FoxO3a and disease progression. World J Biol Chem 5, 346 (2014).
65. Cautain, B. et al. Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling. PLoS One 11, e0167491 (2016).
66. Das, T. P., Suman, S., Alatassi, H., Ankem, M. K. & Damodaran, C. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Cell Death Dis 7, e2111–e2111 (2016).
67. Rinkenbaugh, A. L. & Baldwin, A. S. The NF-κB Pathway and Cancer Stem Cells. Cells 5 (2016).
68. Ruiz de Porras, V. et al. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. Sci Rep 6, 24675 (2016).
69. Li, W., Chen, C., Liu, Z. & Hua, B. Targeting Signal Transducer and Activator ofTranscription 3 for Colorectal Cancer Prevention and Treatment with Natural Products. Cancer Transl Med 2, 48 (2016).
70. Samuel, T., Fadlalla, K., Gales, D. N., Putcha, B. D. & Manne, U. Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer 14, 599 (2014).
71. Shin, J.-Y., Kim, J.-O., Lee, S. K., Chae, H.-S. & Kang, J.-H. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 10, 425 (2010).
72. Körber, M. I., Staribacher, A., Ratzenböck, I., Steger, G. & Mader, R. M. NFκB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma. Anticancer Res 36, 1631–9 (2016).
73. Kang, Y. et al. Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathway. Onco Targets Ther 9, 7373–7384 (2016).
74. Shi, J. & Wei, P.-K. Interleukin-8: A potent promoter of angiogenesis in gastric cancer. Oncol Lett 11, 1043–1050 (2016).
75. Gao, H., Lan, X., Li, S. & Xue, Y. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. Tumor Biol 39, 101042831769836 (2017).
76. Deng, Y., Verron, E. & Rohanizadeh, R. Molecular Mechanisms of Anti-metastatic Activity of Curcumin. Anticancer Res 36, 5639–5648 (2016).
77. Hammond, W. A., Swaika, A. & Mody, K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8, 57–84 (2016).
78. Valenzuela, M. M. A., Neidigh, J. W. & Wall, N. R. Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy 3 (2014).
79. Housman, G. et al. Drug Resistance in Cancer: An Overview. Cancers (Basel) 6, 1769–1792 (2014).
80. González-Sarrías, A., Ma, H., Edmonds, M. E. & Seeram, N. P. Maple polyphenols, ginnalins A–C, induce S- and G2/M-cell cycle arrest in colon and breast cancer cells mediated by decreasing cyclins A and D1 levels. Food Chem 136, 636–642 (2013).
81. de la Cueva, A. et al. Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts. PLoS One 8, e64961 (2013).
82. Jiang, B., Liu, F., Liu, Z., Zhang, T. & Hua, D. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. Tumor Biol 37, 9465–9472 (2016).
83. Barve, A. et al. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm Drug Dispos 30, 356–65 (2009).
84. Zhao, L., Au, J. L.-S. & Wientjes, M. G. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) 2, 241–9 (2010).
85. Livak, K. J. & Schmittgen, T. D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods 25, 402–408 (2001).
86. Xia, J., Benner, M. J. & Hancock, R. E. W. NetworkAnalyst - integrative approaches for protein–protein interaction network analysis and visual exploration. Nucleic Acids Res 42, W167–W174 (2014).
87. Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. Nucleic Acids Res 41, D1228–D1233 (2013).
88. Wang, X. et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res 45 (2017).
89. Korb, O., Stützle, T. & Exner, T. E. PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design. In 247–258 https://doi.org/10.1007/11839088_22 (Springer, Berlin, Heidelberg, 2006).
90. ten Brink, T. & Exner, T. E. Influence of Protonation, Tautomeric, and Stereoisomeric States on Protein−Ligand Docking Results. J Chem Inf Model 49, 1535–1546 (2009).
91. ten Brink, T. & Exner, T. E. A combined combinatorial and pKa-based approach to ligand protonation states. J Cheminform 2, P43 (2010).